We have demonstrated that although CD13 is heavily glycosylated in both cancers (CDX) and normal tissues (liver and kidney), the nature (identity and position) of this glycosylation differs across tissues and as such poses tissue-specific structural hindrance to the detection by CD13 antibodies depending on the epitope-binding recognition of the antibody in question. This evidence concerns the gene ANPEP and cancer.